2 Biotech Stocks to Buy Hand Over Fist in October

October typically isn't a time investors look forward to in the markets. It has historically been associated with equities moving in the wrong direction, and sometimes experiencing full-blown market crashes. The broader market has performed pretty well so far this year, but could that come to a halt in October? Maybe.No matter what happens, investing in companies that will get through bear markets and perform well over the long run is always a good idea. Let's consider two such stocks in the biotech industry: Amgen (NASDAQ: AMGN) and Vertex Pharmaceuticals (NASDAQ: VRTX).While it might not look like it initially, Amgen has had trouble with top-line growth in recent years. In the second quarter, the company's revenue -- helped by the October acquisition of Horizon Therapeutics -- increased by 20% year over year to $8.4 billion. Amgen's sales increased by 5% organically, not terrible for a biotech giant, but not particularly impressive either. The good news is that it's making moves to improve on that front.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool